|Systematic (IUPAC) name|
|Bioavailability||increases when administered with food|
|Mol. mass||877.031 g/mol|
|(what is this?)|
A review of alternative regimens for prevention of active tuberculosis in HIV-negative individuals with latent TB found that a weekly, directly observed regimen of rifapentine with isoniazid for three months was as effective as a daily, self -administered regimen of isoniazid for nine months. But the rifapentine-isoniazid regimen had higher rates of treatment completion and lower rates of hepatotoxicity . However the rates of treatment-limiting adverse events were higher in the rifapentine-isoniazid regimen. 
Rifapentine was first synthesized in 1965 by the same company that produced rifampin. The drug was approved by the Food and Drug Administration (FDA) in June 1998. It is synthesized in one step from rifampicine.